Replies to post #919 on Biotech Values

[DewDiligence]

Re: CA4P and QTc-prolongation:

>> The data in Clinical Cancer Research article was already published 11/2002 <<

mid_swe: What exactly are you referring to? In your reference, I see mention of a QTc measurement for a single male patient, age 55. T.i.a.

In any event, I do not think it matters how old or new the QTc-prolongation problem is (except in assessing OXGN management’s integrity). If CA4P produces clinically significant QTc-prolongation, there is a problem.

At this point my attitude is “guilty until proven innocent.” In other words, I want to see convincing evidence that cardiac toxicity will not cause CA4P to have labeling restrictions that might affect its uptake in the commercial marketplace. Regards, Dew